China has granted Tasly Pharmaceutical (SHA:600535) clinical trial approval for its allogeneic adipose-derived mesenchymal stromal cell injection for acute ischemic stroke, according to a Friday filing with the Shanghai Stock Exchange.
The drug activates vascular regeneration and functional repair of damaged brain tissue in stroke patients, the filing said.
Tasly's injection has also been approved for clinical trial in the US in October 2024, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments